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ORIGINAL ARTICLE
Efficacy and Safety of Monthly 150 mg Oral Ibandronate in 
Women with Postmenopausal Osteoporosis: A Systematic 
Review and Meta-Analysis of Randomized Controlled Trials
Young Ho Lee and Gwan Gyu Song
Division of Rheumatology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea
Background/Aims: The aim of this study was to assess the efficacy and safety of monthly oral 150 mg ibandronate in 
women with postmenopausal osteoporosis (PMO). 
Methods: A systematic review and meta-analysis were performed to determine treatment efficacy and safety outcomes 
between monthly oral 150 mg ibandronate and weekly 70 mg alendronate, daily 2.5 mg ibandronate, and a placebo. 
Results: Eight randomized controlled trials were included in this systematic review and meta-analysis. Once-monthly 150 
mg ibandronate therapy was clinically comparable to weekly 70 mg alendronate, showing increased bone mineral density 
(BMD) in both the lumbar spine and total hip. Pooled data from two cross-over trials showed that significantly more women 
with PMO preferred once-monthly ibandronate therapy to once-weekly alendronate therapy (relative risk [RR], 2.422; 
95% confidence interval [CI], 2.111 to 2.825; p < 1 × 10
-8) and found the monthly ibandronate regimen more convenient 
than the weekly alendronate regimen (RR, 3.096; 95% CI, 2.622 to 3.622; p < 1 × 10
-8). Monthly 150 mg ibandronate 
therapy resulted in a significantly higher change in BMD of the lumbar spine than with the placebo. A once monthly 150 
mg regimen produced greater increases in lumbar spine, total hip, femoral neck, and trochanter BMD than daily treatment, 
with a similar incidence of adverse events between the groups. 
Conclusions: Once monthly 150 mg ibandronate therapy was clinically comparable to weekly 70 mg alendronate, and 
patients strongly preferred the convenience of monthly ibandronate over weekly alendronate. Monthly 150 mg ibandronate 
was superior to, and as well tolerated as, the daily treatment. 
Keywords: Ibandronic acid; Efficacy; Safety; Osteoporosis; Review 
INTRODUCTION
Osteoporosis is a skeletal disorder characterized by low 
bone mass and microarchitectural deterioration of bone 
tissue, predisposing patients to increased fracture risk [1]. 
Osteoporosis is the leading underlying cause of fractures, 
particularly in postmenopausal women, due to the loss 
of estrogen-mediated suppression of bone resorption 
[2]. More than 50% of adults 50 years of age or older are 
estimated to have osteoporosis. Of these, almost 70% are 
women with postmenopausal osteoporosis (PMO) [3].
Bisphosphonates are the standard first-line treatment 
and the most widely used therapy for PMO. However, long-
term compliance with therapy is necessary for optimal 
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outcomes, because poor adherence is associated with 
smaller decreases in bone turnover, lower increases in 
bone mineral density (BMD), and a significantly greater 
risk for fracture [4]. Although suboptimal adherence to 
oral bisphosphonates compromises therapeutic outcomes 
in patients with PMO, long-term compliance to current 
oral bisphosphonates is poor [5]. This is a major limitation 
for long-term effective therapy of bisphosphonates for 
osteoporosis.
Oral bisphosphonates, given once daily or once 
weekly, are currently the mainstay treatment in patients 
with PMO [6]. However, oral once daily or once weekly 
bisphosphonates are inconvenient and challenging for 
some patients, leading to a decrease in adherence to 
treatment and a reduction in antifracture efficacy [7]. 
Although weekly bisphosphonate dosing is associated 
with better adherence than daily dosing, adherence rates 
are suboptimal [8]. No more than 31-44% of women with 
PMO are compliant with their weekly bisphosphonate 
therapy after 1 year [3,7]. The availability of a less frequent 
bisphosphonate regimen would offer patients greater 
convenience and improve therapeutic adherence [3].
Ibandronate is a potent oral bisphosphonate approved 
by the US Food and Drug Administration for use as a once 
monthly oral or quarterly intravenous (IV) treatment for 
PMO [9]. Once monthly oral and quarterly IV ibandronate 
have been approved and marketed worldwide including 
Europe, the US, and Asia [10]. Ibandronate has greater 
antiresorptive efficacy than either alendronate or 
risedronate in animal models [10]. The high potency, 
safety, and tolerability profile of ibandronate enable 
its increased dosing interval, while maintaining an 
advantageous therapeutic profile. A once monthly oral 150 
mg dose is the recommended available dosage regimen 
[11]. The aim of this study was to assess the efficacy 
and safety of a monthly oral 150 mg ibandronate dose, 
compared with a daily and monthly bisphosphonate 
regimen or a placebo, in women with PMO.
METHODS
Identification of eligible studies and data extraction
We performed a literature search for randomized 
controlled trials (RCTs) that examined monthly oral 
150 mg ibandronate treatment for osteoporosis. 
Literature searches were performed using MEDLINE 
(to June 2010) and the Cochrane Controlled Trials 
Register (to June 2010) to identify relevant studies. 
The following key words and subject terms were used 
in the searches: “ibandronate,” “bone mineral density,” 
and “osteoporosis.” All references in the articles were 
reviewed to identify additional studies not included in 
the electronic databases. RCTs were included if they met 
the following criteria: the study compared monthly oral 
150 mg ibandronate with a placebo and daily or weekly 
bisphosphonate for efficacy or safety. 
The following information was extracted from each 
study: first author, year of publication, country in which 
the study was conducted, menopausal state, length of 
follow-up, preference and convenience numbers, skeletal 
sites evaluated for BMD, mean and standard deviation 
of BMD (change-from-baseline), and safety outcomes. 
Change-from-baseline was reported as a percent change. 
The safety outcome was the number of patients who had 
experienced side effects, gastrointestinal (GI) adverse 
effects, withdrawal, and withdrawal due to adverse 
effects. We quantified the methodological qualities of 
studies using Jadad scores [12]. These assessments were 
based on: 1) whether the randomization method was 
appropriate, 2) whether double blindness was mentioned 
in the trial and whether the trial was appropriately 
performed; and 3) whether the number of patients who 
withdrew, and their reasons, were clearly stated. Jadad 
scores ranged from 0 to 5, and higher scores denoted 
better trial quality. 
Evaluations of statistical associations
The trial outcome effect sizes were expressed as the 
relative risk (RR) for binary data, such as number of 
adverse effects or weighted mean difference (WMD) for 
changes in BMD and corresponding 95% confidence 
intervals (CIs). We assessed within- and between-study 
variation and heterogeneity using Cochran’s Q-statistics 
[13]. The heterogeneity test was used to assess the null 
hypothesis that all studies were evaluating the same 
effect. When a significant Q-statistic (p < 0.10) indicated 
heterogeneity across studies, the random effect model 
was used for the meta-analysis and, if not, the fixed 
effect model was used. The fixed effect model assumes 
that all studies estimate the same underlying effect and 
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the effect of heterogeneity using I
2 = 100% × (Q - df) / 
Q [14], where I
2 measures the degree of inconsistency 
between studies and determines whether the percent 
total variation across studies is due to heterogeneity 
rather than to chance. I
2 ranges between 0% and 100%; 
I
2 values of 25%, 50%, and 75% are referred to as low, 
moderate, and high estimates. Statistical analyses were 
conducted using the comprehensive meta-analysis 
computer program (Biosta, Englewood, NJ, USA).
RESULTS
Studies included in the meta-analysis
Twenty-one studies were identified by electronic and 
manual searches, and 11 were selected for a full-text 
review based on titles and abstracts [15-25]. However, 
three of the 11 were excluded; one study was a RCT 
that did not compare monthly ibandronate [23], and 
two contained duplicate data [24,25]. Thus, eight 
studies met the inclusion criteria [15-22]. Five studies 
addressed monthly 150 mg ibandronate vs. weekly 70 mg 
alendronate [15,18-21], but two were cross-over studies 
[18,21]. Two studies assessed monthly 150 mg ibandronate 
vs. placebo [16,17,26], and one study considered monthly 
150 mg ibandronate vs. daily 2.5 mg ibandronate [22]. 
Relevant features of the studies included in the systematic 
review and meta-analysis are provided in Table 1. Follow-
up periods ranged from 6 to 24 months. Jadad scores 
ranged from 1 to 3, and the median score was 3 (Table 1). 
We performed a meta-analysis if there were at least two 
comparisons.
Trial outcomes of monthly 150 mg ibandronate vs. 
weekly 70 mg alendronate: RCTs
Three RCTs compared monthly 150 mg ibandronate 
with weekly 70 mg alendronate in patients with PMO 
[15,19,20] (Table 1). However, two studies were about 
the same subjects [15,19]. The study by Emkey et al. [15] 
reported additional data from the monthly oral therapy 
with ibandronate for osteoporosis intervention (MOTION) 
study from Miller et al. [19] The MOTION study revealed 
that once-monthly ibandronate was clinically comparable 
to weekly alendronate and increased BMD after 12 months 
in both the lumbar spine and total hip [19]. Mean relative 
12-month changes were 5.1% and 5.5% in lumbar spine 
and 2.9% and 3.0% in total hip BMD with once-monthly 
ibandronate and weekly alendronate, respectively. Emkey 
et al. [15] revealed comparable efficacy of once monthly 
150 mg ibandronate therapy in terms of BMD response. 
The percentage of patients with mean lumbar spine and 
total hip BMD gains above baseline (responders) were 90% 
and 87%, respectively, for ibandronate and 92% and 90%, 
respectively, for alendronate.
No significant difference was observed between the two 
treatment regimens in terms of side effects such as all 
adverse effects, GI adverse effects, number of withdrawals, 
and withdrawals due to adverse effects (Table 2, Fig. 
1). Cooper et al. [20] compared treatment compliance 
in patients receiving either once monthly ibandronate 
plus a patient support program (PSP), or once weekly 
alendronate. Compliance was significantly higher in the 
ibandronate/PSP group than that in the alendronate group 
(56.6% [306/541] vs. 38.6% [198/513], p < 0.0001), with 
47% relative improvement in the ibandronate/PSP group. 
Significantly more patients discontinued the study from 
the alendronate group (25.3%, 134/529), as compared to 
the ibandronate/PSP group (19.6%, 107/547, p = 0.023).
Trial outcomes of monthly 150 mg ibandronate 
vs. weekly 70 mg alendronate: randomized cross-
over studies
Two randomized open-label, cross-over trials were 
conducted to assess preference and convenience for once-
monthly ibandronate vs. once-weekly alendronate [18,21]. 
The primary endpoint was the percentage of patients 
who preferred the ibandronate monthly regimen to the 
alendronate weekly regimen. The secondary endpoint was 
the percentage of patients perceiving that the monthly 
ibandronate regimen was more convenient than weekly 
dosing of alendronate. Pooled data from two RCTs showed 
differences between the two groups in terms of preference 
and convenience (RR, 2.422, 95% CI, 2.111 to 2.825, p < 
1 × 10
-8; RR, 3.096, 95% CI, 2.622 to 3.622, p < 1 × 10
-8, 
respectively) (Table 2, Fig. 2). Significantly more women 
with PMO preferred once monthly ibandronate therapy to 
once weekly alendronate therapy and found the monthly 
ibandronate regimen more convenient than the weekly 
alendronate regimen.Lee YH and Song gg. Efficacy and safety of monthly 150 mg oral ibandronte    343
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Table 1. Characteristics of individual studies included in the systematic review and meta-analysis
Study No. Subject Study design (name) Comparison Follow-up 
period, 
mon
Results Jadad 
score E C
Emkey 
et al. 
2009 [15]
874 859 PMO Randomized, multinational, 
multi-center, double-blind, 
double-dummy, parallel-
group, noninferiority study 
(MOTION)
Monthly 150 mg 
ibandronate vs. weekly 
70 mg alendronate 
12 Monthly ibandronate 
produced comparable 
efficacy in terms of 
trochanter and femoral 
neck BMD response, and 
GI tolerability
5
Miller 
et al. 
2008 [19]
874 859 PMO Randomized, multinational, 
multi-center, double-blind, 
double-dummy, parallel-
group, noninferiority study 
(MOTION)
Monthly 150 mg 
ibandronate vs. weekly 70 
mg alendronate 
12 Monthly ibandronate was 
clinically comparable to 
weekly alendronate by 
increasing BMD in both the 
lumbar spine and total hip
5
Cooper 
et al. 
2006 [20]
547 529 PMO Randomized, open-label,
multi-center st udy 
(PERSIST)
Monthly 150 mg 
ibandronate vs. weekly 70 
mg alendronate 
6 Compliance was 
significantly higher in 
the ibandronate plus a 
patient support program 
group compared with the 
alendronate group (56.6% 
vs. 38.6%, p < 0.0001)
3
Emkey 
et al. 
2005 [21]
173 173 PMO Prospective, randomized, 
open-label, multi-center 
study with a two-period 
and two-sequence cross-
over treatment (BALTO)
Monthly 150 mg 
ibandronate vs. weekly 70 
mg alendronate 
6 More women preferred 
monthly ibandronate 
to weekly alendronate 
(71.4% vs. 28.6%, p < 
0.0001)
3
Hadji 
et al. 
2008 [18]
336 338 PMO Prospective, randomized, 
open-label, multi-center 
study with a two-period 
and two-sequence cross-
over treatment (BALTO II)
Monthly 150 mg 
ibandronate vs. weekly 70 
mg alendronate 
6 More women preferred 
monthly ibandronate 
to weekly alendronate 
(70.6% vs. 29.4%, p < 
0.0001)
3
McClung 
et al. 
2009 [16]
77 83 PMO Randomized, double-blind, 
placebo-controlled study
Monthly 150 mg 
ibandronate vs. placebo
12 Once monthly ibandronate 
improved spine (difference 
of 4.1%, p < 0.0001), hip, 
trochanter, and femoral 
neck BMD
3
Lewiecki
et al. 
2009 [17]
47 46 Women,
BMD ≤ 
T-
score - 
2.0
Randomized, double-
blind, placebo-controlled, 
parallel-group study
Monthly 150 mg 
ibandronate vs. placebo
12 Once monthly ibandronate 
improved hip (treatment 
differences: 2.2%, p = 
0.005) and spine BMD
2
Reginster
et al. 
2006 [22]
401 402 PMO Randomized, double blind,
parallel group, phase 
III, non-inferiority study 
(MOBILE)
Monthly 150 mg 
ibandronate vs. daily 2.5 
mg ibandronate 
24 Once monthly oral 
ibandronate is as effective 
and well tolerated as daily 
treatment
3
E, experimental group; C, control group; PMO, postmenopausal osteoporosis; MOTION, the monthly oral therapy with ibandronate for 
osteoporosis intervention study; PERSIST, the persistence study of ibandronate versus alendronate; BALTO, the Bonviva alendronate 
trial in osteoporosis; MOBILE, the monthly oral ibandronate in ladies; BMD, bone mineral density; GI, gastrointestinal. 344    The Korean Journal of Internal Medicine Vol. 26, No. 3, September 2011
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Trial outcomes of monthly 150 mg ibandronate vs. 
placebo
Two RCTs were conducted on monthly 150 mg 
ibandronate vs. a placebo [16,17,27]. McClung et al. [16] 
showed that subjects treated with ibandronate achieved 
larger increases in lumbar spine BMD after 1 year, as 
compared to a placebo group (3.7% vs. -0.4%, p < 0.0001). 
Lewiecki et al. [17] revealed that ibandronate increased 
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Figure 1. Meta-analysis of all studies (A) and gastrointestinal adverse effects (B) for monthly 150 mg ibandronate vs. weekly 70 mg 
alendronate. CI, confidence interval.
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Figure 2. Meta-analysis of preference (A) and convenience (B) for monthly 150 mg ibandronate vs. weekly 70 mg alendronate. CI, confi-
dence interval.
a B
Table 2. Meta-analysis of randomized controlled trials of monthly oral 150 mg ibandronate 
Study type Outcome No. of  Test of association Test of heterogeneity
studies RR 95% CI p value Q p value I
2
Monthly 150 mg
 ibandronate vs.
 weekly 70 mg
 alendronate 
All AE
GI AE
All withdrawals 
Withdrawals due to AE
2
2
2
2
0.989
1.059
0.916
1.044
0.913-1.071
0.937-1.198
0.645-1.302
0.787-1.386
0.778
0.357
0.626
0.765
2.7
0.0
3.9
0.0
0.094
0.827
0.046
0.821
64.2
0
74.9
0
BALTO studies Preference 2 2.422 2.111-2.825 < 1 × 10
-8 0.0 0.792 0
Convenience 2 3.096 2.622-3.656 < 1 × 10
-8 0.3 0.536 0
Monthly 150 mg 
 ibandronate vs.
 placebo
Lumbar spine change in BMD 2 4.054
a 1.987-6.121 0.0001 0.0 0.939 0
RR, relative risk; CI, confidence interval; AE, adverse effect; GI, gastrointestinal; BALTO, the Bonviva alendronate trial in osteoporosis; 
BMD, bone mineral density.
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total hip and lumbar spine BMD more than a placebo at 
12 months (differences: 2.2%, p = 0.005, 4.3%, p < 0.001). 
Monthly 150 mg ibandronate therapy showed significantly 
higher changes in BMD of the lumbar spine than a placebo 
(WMD, 4.054; 95% CI, 1.987 to 6.121; p = 0.0001) (Fig. 3). 
Trial outcomes of monthly 150 mg ibandronate vs. 
daily 2.5 mg ibandronate 
A 2-year, randomized, double blind, parallel group, 
phase III, non-inferiority study (monthly oral ibandronate 
in ladies, MOBILE) was conducted comparing monthly 
150 mg ibandronate vs. daily 2.5 mg ibandronate [22]. 
Substantial increases in lumbar spine BMD were seen in 
both groups (5.0 and 6.6% in the daily and once monthly 
groups, p < 0.001). The once monthly 150 mg regimen 
produced greater increases in total hip, femoral neck, 
and trochanter BMD (p < 0.05). A similar proportion 
of patients in the once monthly and daily treatments 
withdrew from treatment. The incidences of adverse 
events, drug related adverse events, and drug-related 
adverse events leading to withdrawal were balanced 
between the treatments. The once monthly 150 mg 
regimen was superior to the daily regimen.
Heterogeneity, publication bias, and sensitivity 
analysis
Between-study heterogeneity was found during analyses 
of all adverse events and all withdrawals of monthly 150 
mg ibandronate vs. weekly 70 mg alendronate. It was 
difficult to correlate the funnel plot, because of the small 
number of studies included. Egger’s test could not be 
conducted due to the small number of studies. 
DISCUSSION
We systemically combined and reviewed the clinical 
data of eight RCTs that examined monthly oral 150 mg 
ibandronate treatment for osteoporosis to assess the ef-
ficacy and safety of monthly oral 150 mg ibandronate in 
women with PMO. Once-monthly 150 mg ibandronate 
therapy was clinically comparable to weekly 70 mg alen-
dronate without a significant difference in side effects. Use 
of the higher dose resulted in concerns about increased ad-
verse effects. The most common adverse effects reported 
with bisphosphonates affect the upper GI system. Monthly 
oral ibandronate shows adverse effect frequencies, includ-
ing GI adverse effects, that are similar to weekly alendro-
nate.
Adherence to weekly dosing is improved, as compared 
to daily regimens, but remains suboptimal [7]. One of the 
proposed benefits of once monthly ibandronate therapy is 
improved compliance [28]. Adherence was calculated as 
the ratio of the total days of therapy to the number of days 
of follow-up, and we tested compliance with the medica-
tion possession ratio, which was defined as the propor-
tion of days in which patients had a supply of medication. 
Significantly more women with PMO preferred once 
monthly ibandronate therapy to once weekly alendronate 
therapy, and the monthly ibandronate regimen was more 
convenient than the weekly alendronate regimen. Non-
inferiority studies are widely accepted for demonstrating 
therapeutic equivalence between alternative regimens 
and are particularly useful for comparing the efficacy of 
a novel agent or regimen to an established therapy [22]. 
Once-monthly ibandronate was noninferior to, and clini-
cally comparable to, weekly alendronate with an increased 
BMD in both the lumbar spine and total hip after 12 
months of treatment [22].
The currently available monthly oral ibandronate regi-
men was approved in 2005, based on the 2-year MOBILE 
bridging trial [22]. At 2 years, substantial increases in lum-
bar spine BMD were observed in the once monthly (6.6%) 
and daily (5.0%) groups. Significantly greater percentages 
of patients achieved measurable 2-year BMD gains in the 
lumbar spine and total hip with the 150 mg/mon regimen 
vs. 2.5 mg/day. The once monthly 150 mg regimen pro-
duced greater increases in BMD than the daily treatment, 
with a similar incidence of adverse events between the 
groups. The monthly 150 mg ibandronate dose was supe-
Lumbar BMD Statistics for each study
Std diff Lower Upper
in means
McCkung, 2009 1.527
Alendronate   lbandronate
0.212 1.843 0.0011
-1.00 -0.50 0.00 0.50 1.00
0.398 -0.013 1.808 0.0575
0.479 0.229 1.729 0.0002
Lewieecki, 2009
limit limit p value
Std diff in means
and 95% CI
Figure 3. Meta-analysis of change in lumbar spine bone mineral 
density for monthly 150 mg ibandronate vs. placebo. CI, confidence 
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rior to the daily 2.5 mg dose.
Previous meta-analyses have shown dose-dependent 
efficacy of ibandronate [27,29]. The efficacy of ibandronate 
in reducing nonvertebral fracture risk was evaluated in 
two meta-analyses [27,29]. Patients were assigned to dose-
level groups, based on annual cumulative exposure (ACE) 
to ibandronate. The once-daily 2.5 mg and once monthly 
oral 150 mg regimens are equivalent to an ACE of 5.5 and 
10.8 mg, respectively. A high dose level, including once-
monthly 150 mg (ACE ≥ 10.8 mg), showed a significant 
reduction in the rate of nonvertebral fractures than did a 
lower dose (2.5 mg daily regimen; ACE, 5.5 mg) (adjusted 
hazard ratio, 0.620; 95% CI, 0.396 to 0.974; p = 0.038). 
Ibandronate regimens with an ACE ≥ 10.8 mg showed a 
38% reduction for all nonvertebral fractures versus daily 
oral ibandronate (ACE, 5.5 mg). The effect of ibandronate 
on nonvertebral fractures was dose-dependent.
The present systematic review and meta-analysis has 
several shortcomings that must be considered. First, the 
possibility of publication bias is always a concern, and it 
should be recognized that publication bias is difficult to 
exclude, particularly when the number of incorporated 
studies is small, as in the present study. Second, 
heterogeneity of clinical features, such as, race, age, and 
study quality, which is of fundamental importance to a 
meta-analysis, may confound meta-analysis findings. 
Third, although our systematic review included eight 
RCTs, the subgroup meta-analysis was based on a smaller 
number of studies. Only two RCTs were included in our 
meta-analysis for each subject; thus, findings should be 
regarded with caution. Third, all of the studies included 
in this systematic review were funded by drug companies. 
Therefore, the results should be interpreted with caution. 
In conclusion, once monthly 150 mg ibandronate therapy 
was noninferior and clinically comparable to weekly 70 mg 
alendronate. Strong patient preference and convenience 
for monthly ibandronate over weekly alendronate was 
found in women with PMO. Monthly 150 mg ibandronate 
was superior to, and as well tolerated as, daily treatment. 
The availability of a less frequent bisphosphonate regimen, 
such as once monthly ibandronate, enables patients 
to choose a dosing regimen that best fits their lifestyle 
and improves patient satisfaction and adherence to 
osteoporosis treatment, which increases the effectiveness 
of osteoporosis therapy. Once monthly 150 mg ibandronate 
provided an effective therapeutic option for PMO.
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